Becton Dickinson settles expenses over infusion pump dangers, SEC says

WASHINGTON (Reuters) – The U.S. Securities and Alternate Fee mentioned on Monday that it had settled expenses with Becton Dickinson (NYSE:BDX) and Co. (BD) over allegations it misled buyers about dangers related to its Alaris infusion pump.

The SEC mentioned Becton Dickinson agreed to pay a $175 million civil penalty to settle the costs, which additionally allege that the corporate overstated its revenue by failing to reveal the prices of software program repairs related to the pump.BD didn’t admit to or deny the SEC’s expenses, however mentioned in an announcement {that a} settlement is the “proper plan of action to totally resolve this matter and transfer ahead.”

BD mentioned the corporate wouldn’t have to situation monetary restatements because of the settlement.